Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China
· Delayed Price · Currency is CNY 10.52
+1.03 (10.85%)
Apr 29, 2026, 3:04 PM CST
SHE:301060 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | -15.42 | -109.44 | -141.59 | 617.32 | 203.84 | Upgrade
|
| Depreciation & Amortization | 79.24 | 73.28 | 65.36 | 78.24 | 59.35 | Upgrade
|
| Other Amortization | 23.87 | 30.33 | 18.08 | 20.03 | 11.24 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.23 | -5.88 | -1.93 | 0.36 | -1.04 | Upgrade
|
| Asset Writedown & Restructuring Costs | 16.6 | 15.89 | 11.07 | 158.37 | 1.07 | Upgrade
|
| Loss (Gain) From Sale of Investments | -6.44 | 12.17 | 1.77 | -3.13 | -10.17 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 25.67 | 130.67 | 55.77 | 15.26 | Upgrade
|
| Other Operating Activities | 10.19 | 72.57 | 6.05 | 140.67 | 67.51 | Upgrade
|
| Change in Accounts Receivable | 117.95 | 218.81 | 1,061 | -1,522 | -298.03 | Upgrade
|
| Change in Inventory | 32.15 | 9.43 | 14.84 | -273.18 | 0.69 | Upgrade
|
| Change in Accounts Payable | -5.61 | -121.58 | -604.36 | 828.74 | 173.11 | Upgrade
|
| Change in Other Net Operating Assets | 0.94 | 19.93 | 5.09 | - | - | Upgrade
|
| Operating Cash Flow | 268.85 | 216.31 | 546.99 | 84.17 | 223.51 | Upgrade
|
| Operating Cash Flow Growth | 24.29% | -60.45% | 549.88% | -62.34% | 33.14% | Upgrade
|
| Capital Expenditures | -58.49 | -76.62 | -398.89 | -230.08 | -118.88 | Upgrade
|
| Sale of Property, Plant & Equipment | 7.84 | 5.6 | 3.99 | 4.68 | 5.49 | Upgrade
|
| Cash Acquisitions | - | - | -11.1 | - | - | Upgrade
|
| Divestitures | 3.52 | 3.8 | - | 0 | - | Upgrade
|
| Investment in Securities | -79.83 | -2 | 6.94 | 395.94 | -296.9 | Upgrade
|
| Other Investing Activities | 4.08 | 0.63 | 0.56 | 9.51 | 6.88 | Upgrade
|
| Investing Cash Flow | -122.88 | -68.58 | -398.5 | 180.05 | -403.41 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 4 | Upgrade
|
| Long-Term Debt Issued | 50 | 122.93 | 368.64 | 198.01 | - | Upgrade
|
| Total Debt Issued | 50 | 122.93 | 368.64 | 198.01 | 4 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -2 | Upgrade
|
| Long-Term Debt Repaid | -135.8 | -236.09 | -186.68 | -35.45 | -18.77 | Upgrade
|
| Total Debt Repaid | -135.8 | -236.09 | -186.68 | -35.45 | -20.77 | Upgrade
|
| Net Debt Issued (Repaid) | -85.8 | -113.16 | 181.96 | 162.57 | -16.77 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 158.55 | Upgrade
|
| Repurchase of Common Stock | - | -12.75 | -10.26 | - | - | Upgrade
|
| Common Dividends Paid | -92.7 | -7.36 | -136.71 | -125.61 | -0.3 | Upgrade
|
| Dividends Paid | -92.7 | -7.36 | -136.71 | -125.61 | -0.3 | Upgrade
|
| Other Financing Activities | -95.23 | -46.99 | 9.74 | 13.53 | -21.73 | Upgrade
|
| Financing Cash Flow | -273.73 | -180.25 | 44.73 | 50.48 | 119.75 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.03 | - | -0.57 | -0.56 | 0.02 | Upgrade
|
| Net Cash Flow | -127.79 | -32.52 | 192.65 | 314.15 | -60.12 | Upgrade
|
| Free Cash Flow | 210.36 | 139.7 | 148.1 | -145.91 | 104.63 | Upgrade
|
| Free Cash Flow Growth | 50.59% | -5.68% | - | - | -15.16% | Upgrade
|
| Free Cash Flow Margin | 14.53% | 8.02% | 8.85% | -3.48% | 5.88% | Upgrade
|
| Free Cash Flow Per Share | 0.55 | 0.34 | 0.37 | -0.36 | 0.30 | Upgrade
|
| Cash Income Tax Paid | 50.48 | 48.43 | 121.5 | 194.14 | 77.25 | Upgrade
|
| Levered Free Cash Flow | 216.32 | 187.84 | 207.16 | -378.79 | 38.83 | Upgrade
|
| Unlevered Free Cash Flow | 216.32 | 194.6 | 212.26 | -373.5 | 40.87 | Upgrade
|
| Change in Working Capital | 159.59 | 101.72 | 457.5 | -983.47 | -123.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.